Randomised controlled trial
SURMOUNT-1
Jastreboff AM et al., NEJM 2022;387:205–216
- Participants
- 2,539
- Duration
- 72 weeks
- Comparator
- vs. placebo, alongside lifestyle intervention
At the highest dose (15 mg), participants lost an average of ~22.5% of baseline body weight versus ~3% on placebo. Trial participants had BMI ≥ 30, or ≥ 27 with a weight-related comorbidity.
Read the full paper
